Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Details : Based on discussions with MHLW and PMDA, Eisai applied to PMDA for permission to utilize "prior assessment consultation" process for BAN2401 (lecanemab), an investigational anti-amyloid beta protofibril antibody with aim of shortening review period for t...
Product Name : BAN2401
Product Type : Antibody
Upfront Cash : Inapplicable
April 03, 2022